FFA
FDMT icon

Farther Finance Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Farther Finance Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.66K Hold
125
– – ﹤0.01% 5223
2026
Q1 		$1.23K Sell
125
-507
-80% -$4.41K ﹤0.01% 5044
2025
Q4 		$4.74K Sell
632
-4,320
-87% -$43.8K ﹤0.01% 4336
2025
Q3 		$43K Buy
4,952
+2,674
+117% +$16K ﹤0.01% 2536
2025
Q2 		$8.45K Buy
+2,278
New +$8.01K ﹤0.01% 3159
2025
Q1 		– Sell
-14
Closed -$66 – 4310
2024
Q4 		$78 Hold
14
– – ﹤0.01% 3821
2024
Q3 		$151 Buy
14
+3
+27% +$50 ﹤0.01% 3709
2024
Q2 		$235 Hold
11
– – ﹤0.01% 3467
2024
Q1 		$330 Hold
11
– – ﹤0.01% 3140
2023
Q4 		$223 Buy
+11
New +$145 ﹤0.01% 3206

Other funds holding FDMT

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
APW
Allied Private Wealth Boca Raton, Florida $156M AUM
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Farther Finance Advisors's FDMT Position: Q2 2026 in Review

Farther Finance Advisors held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 125 shares worth $1.66K. The position accounts for ﹤0.01% of the portfolio, ranked #5223.

Farther Finance Advisors first reported a position in FDMT in Q4 2023 and has held it in 10 quarters since. The position peaked at $43K in Q3 2025. 9 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Farther Finance Advisors held 125 shares of 4D Molecular Therapeutics worth $1.66K as of Q2 2026.
  • Farther Finance Advisors left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5223 holding.
  • Farther Finance Advisors first reported a position in 4D Molecular Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Farther Finance Advisors's 4D Molecular Therapeutics position peaked at $43K in Q3 2025.
  • 9 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.